文献类型：期刊文献

英文题名：Pro-senescence neddylation inhibitor combined with a senescence activated β-galactosidase prodrug to selectively target cancer cells

作者：Ni, Shuaishuai[1];Liu, Qian[1];Chen, Xin[2];Ding, Lele[1];Cai, Lili[1];Mao, Fei[2];Shi, Donglei[2];Hoffman, Robert M.[3];Li, Jian[2];Jia, Lijun[1]

机构：[1]Shanghai Univ Tradit Chinese Med, Canc Inst, Longhua Hosp, Shanghai 200032, Peoples R China;[2]East China Univ Sci & Technol, Shanghai Frontiers Sci Ctr Optogenet Techn Cell M, Frontiers Sci Ctr Materiobiol & Dynam Chem, Shanghai Key Lab New Drug Design,Sch Pharm, Shanghai 200037, Peoples R China;[3]Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA

年份：2022

卷号：7

期号：1

外文期刊名：SIGNAL TRANSDUCTION AND TARGETED THERAPY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000852407400001)】；

基金：This work was supported by the National Natural Science Foundation of China (Grant Nos. 81820108022, 22177076, 22037002), Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-10-E00056, 2021-01-07-00-02-E00104), The Scientific and Technological Innovation Action Plan of Science and Technology Commission of Shanghai (20JC1411300), Shanghai Frontiers Science Center of Disease and Syndrome Biology of Inflammatory Cancer Transformation (2021KJ03-12), National Thirteenth Five-Year Science and Technology Major Special Project for New Drug and Development (2017ZX09304001), the Shanghai Frontier Science Research Base of Optogenetic Techniques for Cell Metabolism (2021 Sci & Tech 03-28), the Innovative Research Team of High-level Local Universities in Shanghai and the Chinese Special Fund for State Key Laboratory of Bioreactor Engineering (2060204).

语种：英文